ClinicalTrials.gg
CompletedNCT03362814Updated Jul 28, 2020

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

A Phase 2/3 interventional study of Ravidasvir and Danoprevir in HCV, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2017, registered Nov 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
425
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of Ravidasvir in combination with Danoprevir/r and ribavirin(RBV) by sustain virologic response 12 (SVR12), in treatment-naive, non-cirrhotic, chronic hepatitis C genotype 1 infected patients.

02

Conditions studied

  • HCV

Keywords

  • HCV
  • Ravidasvir
  • SVR12
03

In context

Lead sponsor

Ascletis Pharmaceuticals Co., Ltd. is the lead sponsor of 25 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infection with Chronic genotype 1confirmed at screening;
  • Anti-HCV positive;
  • HCV RNA ≥1 × 10000IU / mL;
  • Not treated with interferon and / or any other direct-acting antiviral (DAA) drug;
  • Non-cirrhotic;
  • Voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  • genotypes 2 to 7 or undetectable HCV genotype or mixed HCV genotype;
  • Fibroscan detection result > 12.9kPa or Histopathological examination result of patients is with cirrhosis;
  • Past or existing evidence of the presence of non-HCV-induced chronic liver disease;
  • Previous history of hepatocellular carcinoma, or suspected hepatocellular carcinoma found prior to screening, or suspected abdominal hepatoblastoma at screening or AFP>100ng/mL;
  • Anti-HAV (IgM) 、 、anti-HEV (IgM) or anti- is positive;
  • \<18 or≥30 kg/m2;
  • ANC\<1.5×109/L、\<100×109/L、HB\<110g/L(female)or\<120g/L(male);>1.5; or AST≥5*;≥2*ULN(DBIL≥ 35%TBIL);Cr≥1.5*ULN;
  • Others as specified in detailed protocol.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
425 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Ravidasvir + Danoprevir + Ritonavir + Ribavirin

    Drug: Ravidasvir · Drug: Danoprevir · Drug: Ritonavir · Drug: Ribavirin 100 MG

  • Placebo comparator
    Placebo Group

    Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo

    Drug: Ravidasvir Placebo · Drug: Danoprevir Placebo · Drug: Ritonavir Placebo · Drug: Ribavirin Placebo

Interventions

  • Ravidasvir 200mg tablet administered orally once daily

    Also known as: ASC16

  • Danoprevir 100mg tablet administered orally twice daily

    Also known as: ASC08

  • Ritonavir 100mg tablet administered orally twice daily

  • Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 1000mg and ≥75kg = 1200mg)

  • DrugRavidasvir Placebo

    Ravidasvir Placebo tablet administered orally once daily

  • DrugDanoprevir Placebo

    Danoprevir Placebo tablet administered orally twice daily

  • DrugRitonavir Placebo

    Ritonavir Placebo tablet administered orally twice daily

  • DrugRibavirin Placebo

    Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(\<75kg = 5 tablets and ≥75kg = 6 tablets)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants achieving sustained Virologic response 12 weeks after EOT

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks after cessation of therapy

    Time frame: Post treatment Week 12

  2. Adverse events leading to permanent discontinuation of study drug

    Time frame: baseline to week 12

Secondary outcomes

  1. Percentage of Participants achieving sustained Virologic response 4 weeks after EOT

    SVR4 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 4 weeks after cessation of therapy

    Time frame: Post treatment Week 4

  2. Percentage of Participants achieving sustained Virologic response 24 weeks after EOT

    SVR24 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 24 weeks after cessation of therapy

    Time frame: Post treatment Week 24

  3. Quatitation change of HCV RNA compared to baseline after treatment

    Time frame: Baseline to week 1

  4. Percentage of participants with viral breakthrough

    Viral breakthrough was defined as HCV RNA ≥LLOQ after having previously had HCV RNA\< LLOQ while receiving treatment, confirmed with 2 consecutive values

    Time frame: Baseline to week 12

  5. Percentage of participants with viral relapse

    Viral relapse was defined as HCV RNA ≥LLOQ during the post treatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values.

    Time frame: End of treatment to post-treatment week 24

07

Study locations

1 site
  • Peking University People's hospital
    Beijing, Beijing 100044, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Dec 2018, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2017
First posted
Dec 5, 2017
StartActual
Jul 1, 2017
Primary completionActual
Dec 12, 2018
CompletionActual
Apr 24, 2019
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03362814
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Jul 1, 2017
Primary completion
Dec 12, 2018
Completion
Apr 24, 2019
Last update
Jul 28, 2020

Study contacts

Yahong Chen, Master
study director · Ascletis Pharmaceuticals Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ravidasvir · Danoprevir

Start the discussion